Key Companies in the AAV Vector Manufacturing Market: Thermo Fisher Scientific, Catalent Gene Therapy, Lonza Group, Oxford Biomedica, FUJIFILM Diosynth Biotechnologies, WuXi Advanced Therapies, ...

Prof. Paulo Eduardo Stanga presented new data supporting the clinical translation of AAVB-039, AAVantgarde's dual AAV8.ABCA4 gene therapy for STGD1. AAVB-039 uses a dual AAV intein-mediated protein ...

PackGene Biotech announced today at the Cell & Gene Meeting on the Mesa the delivery of client AAV manufacturing projects through the Dyno Frontiers Network, supporting gene therapy programs that use ...

An R75W mutation in the gap junction β2 (GJB2) gene causes severe fragmentation of gap junction plaques, connecting adjacent cells and leading to syndromic hearing loss. In a new experimental study, ...

New non-human primate data show Coave's ligand-conjugated suprachoroidal vector, coAAV-SCS, achieved up to 120-fold higher retinal and ...

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, will participate in the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place in ...

Gene therapy adeno-associated viruses (AAVs)—viruses that can be engineered to deliver DNA to target cells—are unlikely to cause cancer-triggering insertions in humans or monkeys and may contribute to ...

As gene therapy development advances, understanding viral vector quality is becoming just as important as measuring yield. For recombinant adeno-associated virus (rAAV) programs, a key challenge is ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...

SAN FRANCISCO—Kicking off J.P. Morgan week, Dyno Therapeutics announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological ...